Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

3868 - Meta of classical chemotherapy compared with high-dose chemotherapy combined with autologous stem cell transplantation in newly diagnosed medulloblastoma patients after radiotherapy


28 Sep 2019


Poster Display session 1


Tumour Site

Central Nervous System Malignancies


Mengting Zhang


Annals of Oncology (2019) 30 (suppl_5): v143-v158. 10.1093/annonc/mdz243


M. Zhang, C. Liu, X. Xue, H. Zhou, W. Wang, L. Wang

Author affiliations

  • Department Of Radiotherapy, The second hospital of hebei medical University, 050000 - Shijiazhuang/CN


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3868


High-dose chemotherapy combined with autologous stem cell rescue (HDCT+ASCR) has been used to treat newly diagnosed medulloblastoma (MB), but there was no high-level evidence to support its efficacy.


Databases were retrieved, and patients were divided into two groups: group A was radiotherapy combined with HCDT+ASCR, and group B was classical radiotherapy and chemotherapy. The clinical benefit rate, progression-free survival (PFS), total survival (OS) and toxicities data were extracted.


22 clinical trials met the inclusion criteria, 416 in group A and 2331 in group B. There was no difference in CBR between two groups (80.0% vs. 71.5%, P = 0.262). The 3-year PFS (3-y PFS) of group A was significantly better than group B (79.0% vs. 69.5%, P = 0.004). The analysis found that there was no difference between the two groups of the standard risk group or the high-risk group. In the standard risk group, the 5-y PFS of group A was significantly better than group B (83.6% vs.75.6%, P = 0.004). Comparison of 3-y OS and 5-y OS between two groups of all MB patients showed no difference (P = 0.086; P = 0.507), stratified analysis was the same result. The gastrointestinal toxicity in group A was significantly higher than that in group B (P = 0.016), and the level 3/4 ototoxicity in high-risk group A was higher than that in group B (P < 0.001).


HDCT+ASCR was not recommended for newly diagnosed high-risk MB patients. The clinical significance of HDCT+ASCR at the time of initiation in the standard risk group remains to be further explored.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The Second Hospital of Hebei Medical University.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.